AbCellera Biologics Inc.
ABCL
$3.86
-$0.05-1.28%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 9.18M | 6.60M | 10.06M | 12.19M | 21.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.18M | 6.60M | 10.06M | 12.19M | 21.55M |
| Cost of Revenue | -95.26M | 37.92M | 36.47M | 52.65M | -53.75M |
| Gross Profit | 104.43M | -31.32M | -26.42M | -40.46M | 75.30M |
| SG&A Expenses | 19.07M | 17.84M | 19.36M | 18.91M | 15.71M |
| Depreciation & Amortization | 7.54M | 5.74M | 5.61M | 5.51M | 5.42M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.23M | 61.49M | 61.45M | 77.07M | 50.92M |
| Operating Income | -66.05M | -54.89M | -51.39M | -64.87M | -29.38M |
| Income Before Tax | -48.60M | -39.28M | -38.00M | -48.15M | -31.41M |
| Income Tax Expenses | -1.45M | -10.67M | -7.48M | -8.04M | -1.52M |
| Earnings from Continuing Operations | -47.15M | -28.61M | -30.53M | -40.11M | -29.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.15M | -28.61M | -30.53M | -40.11M | -29.89M |
| EBIT | -66.05M | -54.89M | -51.39M | -64.87M | -29.38M |
| EBITDA | -58.52M | -49.16M | -45.78M | -59.36M | -23.99M |
| EPS Basic | -0.16 | -0.10 | -0.11 | -0.14 | -0.10 |
| Normalized Basic EPS | -0.11 | -0.09 | -0.08 | -0.11 | -0.04 |
| EPS Diluted | -0.17 | -0.10 | -0.11 | -0.14 | -0.10 |
| Normalized Diluted EPS | -0.11 | -0.09 | -0.08 | -0.11 | -0.04 |
| Average Basic Shares Outstanding | 290.41M | 289.50M | 288.91M | 287.77M | 286.31M |
| Average Diluted Shares Outstanding | 290.41M | 289.50M | 288.91M | 287.77M | 286.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
